04 · Five things to know · 03
Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint
Must read
What happened
Actinogen said on 11.19 that XanaMIA, a randomized, double-blind, placebo-controlled Phase 2b/3 trial of Xanamem (emestedastat), an oral 11β-HSD1 inhibitor, in 247 people with mild to moderate Alzheimer’s disease and raised pTau181, missed its primary endpoint. The mean benefit on CDR-SB at week 36 was 0.10 points versus placebo (p = 0.65), which the company calls “numerically, but not statistically superior.” In a prespecified subgroup above the median age of 75, 40% versus 22% showed no progression on CDR-SB (p = 0.02), while the mean slowing of 0.39 points was not significant (p = 0.22). The company reports no drug-related serious adverse events and plans talks with FDA and partners on a path in older patients. Claim
Why it matters
A subgroup result after a missed primary can point to the next trial but cannot carry this one. Analysis
What we’re watching
What FDA says about the older-patient path, and the open-label extension results the company plans to present at a future scientific meeting.
Claim CheckMatch
CLAIM CHECK
Match NCT06125951 registers CDR-SB change at 36 weeks as its efficacy primary, with adverse events as a second primary, and 247 enrolled; the release reports that measure. The age subgroup is not a registered primary.
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know